1. The long non-coding RNA GHSROS facilitates breast cancer cell migration and orthotopic xenograft tumour growth.
- Author
-
Thomas PB, Seim I, Jeffery PL, Gahete MD, Maugham M, Crisp GJ, Stacey A, Shah ET, Walpole C, Whiteside EJ, Nelson CC, Herington AC, Luque RM, Veedu RN, and Chopin LK
- Subjects
- Animals, Apoptosis genetics, Breast pathology, Breast Neoplasms immunology, Breast Neoplasms pathology, Disease Progression, Down-Regulation, Female, Gene Expression Profiling, Histocompatibility Antigens Class II genetics, Histocompatibility Antigens Class II immunology, Humans, MCF-7 Cells, Mice, Middle Aged, Oligonucleotide Array Sequence Analysis, Receptors, Ghrelin genetics, Tumor Escape genetics, Xenograft Model Antitumor Assays, Breast Neoplasms genetics, Cell Movement genetics, Gene Expression Regulation, Neoplastic, RNA, Long Noncoding metabolism
- Abstract
Recent evidence suggests that numerous long non‑coding RNAs (lncRNAs) are dysregulated in cancer, and have critical roles in tumour development and progression. The present study investigated the ghrelin receptor antisense lncRNA growth hormone secretagogue receptor opposite strand (GHSROS) in breast cancer. Reverse transcription‑quantitative polymerase chain reaction revealed that GHSROS expression was significantly upregulated in breast tumour tissues compared with normal breast tissue. Induced overexpression of GHSROS in the MDA‑MB‑231 breast cancer cell line significantly increased cell migration in vitro, without affecting cell proliferation, a finding similar to our previous study on lung cancer cell lines. Microarray analysis revealed a significant repression of a small cluster of major histocompatibility class II genes and enrichment of immune response pathways; this phenomenon may allow tumour cells to better evade the immune system. Ectopic overexpression of GHSROS in the MDA‑MB‑231 cell line significantly increased orthotopic xenograft growth in mice, suggesting that in vitro culture does not fully capture the function of this lncRNA. This study demonstrated that GHSROS may serve a relevant role in breast cancer. Further studies are warranted to explore the function and therapeutic potential of this lncRNA in breast cancer progression.
- Published
- 2019
- Full Text
- View/download PDF